openPR Logo
Press release

Acute Respiratory Distress Syndrome Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals

06-15-2024 03:02 AM CET | Health & Medicine

Press release from: ABNewswire

Acute Respiratory Distress Syndrome Pipeline Report 2024 |

DelveInsight's, "Acute Respiratory Distress Syndrome Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Respiratory Distress Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Respiratory Distress Syndrome research. Learn more about our innovative pipeline today! @ Acute Respiratory Distress Syndrome Pipeline Outlook [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report

* June 2024:- Dompe Farmaceutici S.p.A - Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Reparixin as add-on Therapy to SoC in Acute Respiratory Distress Syndrome (RESPIRATIO).
* June 2024:- University of Texas Southwestern Medical Center - The purpose of this study is to conduct a double blinded randomized control trial to determine the safety and efficacy of using IV fentanyl and atropine prior to Less Invasive Surfactant Administration (LISA) procedure in preterm infants with Respiratory Distress Syndrome compared to the local standard of care to perform this procedure without any premedication.
* DelveInsight's Acute Respiratory Distress Syndrome Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Acute Respiratory Distress Syndrome treatment.
* The leading Acute Respiratory Distress Syndrome Companies such as Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast , and others.
* Promising Acute Respiratory Distress Therapies such as STSA-1002, Rhu-pGSN, Reparixin 600mg, Centhaquine, MRG-001, TTI-0102, Dexamethasone , and others.

Stay informed about the cutting-edge advancements in Acute Respiratory Distress Syndrome treatments. Download for updates and be a part of the revolution in cancer care @ Acute Respiratory Distress Syndrome Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Respiratory Distress Syndrome Emerging Drugs Profile

* GEn 1124: GEn1E Lifesciences

GEn 1124 is an investigative small molecule drug being developed in collaboration with GEn1E Lifesciences and Biomedical Advanced Research and Development Authority (BARDA),part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to support the development of the company's novel therapy for acute respiratory distress syndrome (ARDS), The drug candidate is mitogen activated protein kinase 14 inhibitors .Currently, the drug is in Phase II stage of its development for the treatment of acute respiratory distress syndrome.

* ALT-100: Aqualung Therapeutics Corp.

ALT-100 is a "First in Man" immune-based monoclonal antibody (mAb) being developed by Aqualung Therapeutics Corp. ALT-100 antibody is a revolutionary, next generation antibody therapy. The humanized antibody has been developed and optimized by Fusion Antibodies' revolutionary CDRx humanization and ADD develop ability platforms. This humanized monoclonal antibody will block systemic inflammation and will improve survival in the ARDS. ALT-100 inhibits eNAMPT binding to TLR4.Currently the drug is in Phase II stage of clinical trial for the treatment of acute distress respiratory syndrome.

* STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd

STSA 1002 is an investigative recombinant anti-human C5a IgG1 monoclonal antibody which acts by targeting complement C5a inhibitors C5a by specifically binding to anaphylatoxin C5a, C5a loses its ability to bind to receptors and blocks C5a-induced Biological functions, such as neutrophil chemotaxis, degranulation and oxygen respiratory burst, etc., while not affecting C5 cleavage and the formation of membrane attack complex (MAC), retaining the bacteriolytic and bactericidal functions of the complement system, thereby achieving the treatment of viruses, etc. Severe pneumonia, acute lung injury or acute respiratory distress syndrome caused by factors. It is administered through oral and subcutaneous route. Currently, the drug is in Phase I/II stage of its development for the treatment of acute respiratory distress syndrome.

* Descartes 30: Cartesian Therapeutics

Descartes-30 is an off-the-shelf (allogeneic) MSC product engineered with Cartesian's RNA ArmorySM cell therapy platform. Descartes-30 expresses a unique combination of DNases in patients and delivers a targeted treatment directly to the site of disease which eliminates neutrophil extracellular traps which are a key driver of inflammation and clotting in acute respiratory distress syndrome. The drug candidate relies on cell replacements mechanism of action. Currently the drug is in Phase I/II stage of clinical trial for the treatment of acute respiratory distress syndrome.

Learn more about Acute Respiratory Distress Syndrome Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Acute Respiratory Distress Syndrome Unmet Needs [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Respiratory Distress Syndrome Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Acute Respiratory Distress Syndrome treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Acute Respiratory Distress Syndrome Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

* Coverage- Global
* Acute Respiratory Distress Syndrome Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast, and others.
* Acute Respiratory Distress Therapies- STSA-1002, Rhu-pGSN, Reparixin 600mg, Centhaquine, MRG-001, TTI-0102, Dexamethasone, and others.
* Acute Respiratory Distress Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acute Respiratory Distress Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acute Respiratory Distress Syndrome pipeline on our website @ Acute Respiratory Distress Syndrome Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Acute Respiratory Distress Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acute Respiratory Distress Syndrome- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* GEn 1124: GEn1E Lifesciences
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Acute Respiratory Distress Syndrome Key Companies
* Acute Respiratory Distress Syndrome Key Products
* Acute Respiratory Distress Syndrome- Unmet Needs
* Acute Respiratory Distress Syndrome- Market Drivers and Barriers
* Acute Respiratory Distress Syndrome- Future Perspectives and Conclusion
* Acute Respiratory Distress Syndrome Analyst Views
* Acute Respiratory Distress Syndrome Key Companies

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-respiratory-distress-syndrome-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Respiratory Distress Syndrome Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals here

News-ID: 3540062 • Views:

More Releases from ABNewswire

Another Victory for Actelis Networks (NASDAQ: ASNS): $150K+ Order for Multi-Billion Dollar Tier-1 Military Contractor
Another Victory for Actelis Networks (NASDAQ: ASNS): $150K+ Order for Multi-Bill …
Actelis Networks has secured a $150K+ order for a top-tier military contractor. This win follows recent important certifications and a string of contracts across transportation, airports, and utilities. Actelis' momentum across diverse markets, particularly in high-security sectors, suggests potential for significant growth and increased market share in the expanding IoT landscape. In today's digital landscape, where robust cybersecurity and swift implementation of networking solutions are critical, Actelis Networks, Inc. (NASDAQ: ASNS)
Stonegate Firm is a Leading Advocacy Firm for Consumers Who Want to Cancel their Timeshares
Stonegate Firm is a Leading Advocacy Firm for Consumers Who Want to Cancel their …
TULSA, OK - Stonegate Firm [https://stonegatefirm.com/], a premier timeshare exit company, is proud to announce its leadership role in advocating for consumers who wish to cancel their timeshares [https://stonegatefirm.com/timeshare-exit/]. By providing expert assistance and guidance through the often complex and confusing process of timeshare cancellation, Stonegate Firm has positioned itself as a trusted ally for those seeking to escape the financial commitments associated with timeshare ownership. "At Stonegate Firm, we understand the
Atlanta Estate Planning Attorney Trace Brooks Releases New Article About Revocable Living Trusts
Atlanta Estate Planning Attorney Trace Brooks Releases New Article About Revocab …
Atlanta estate planning attorney Trace Brooks (https://www.tracebrookslaw.com/do-i-need-a-revocable-living-trust/), founder of Trace Brooks Law, has published a comprehensive article titled "Do I Need A Revocable Living Trust?" The article provides an in-depth look at the benefits and considerations associated with revocable living trusts, an increasingly popular estate planning tool. Atlanta estate planning attorney Trace Brooks explores the circumstances under which a revocable living trust can be a valuable addition to an individual's estate
Sustainable Manufacturing Market worth $367.2 Billion by 2029, at a CAGR of 11.3%
Sustainable Manufacturing Market worth $367.2 Billion by 2029, at a CAGR of 11.3 …
The global Sustainable Manufacturing Market in terms of revenue was estimated to be worth $215.4 billion in 2024 and is poised to reach $367.2 billion by 2029, growing at a CAGR of 11.3% during the forecast period. The report "Sustainable Manufacturing Market [https://www.marketsandmarkets.com/Market-Reports/sustainable-manufacturing-market-140349832.html?utm_source=ABNewswire&utm_medium=Referral&utm_campaign=PAID-PR] by Offering (Recycled Lithium Ion Batteries, Recycled Metals, Recycled Plastics, Recycled Carbon Fiber, Natural Fiber Composites, Bioplastics & Biopolymers, Water Recycle & Reuse) and Region - Global Forecast

All 5 Releases


More Releases for Respiratory

Global Respiratory Devices and Equipment (Therapeutic) Market | Global Respirato …
The respiratory devices & equipment therapeutic market comprises of the sales of respiratory devices & equipment used for treating the patients with acute or chronic respiratory disorders for instance chronic obstructive pulmonary disease (COPD), sleep disorders, chronic bronchitis, asthma, etc. The market includes sales of respiratory monitoring devices establishments mainly engaged in the manufacturing of oxygen concentrators, nebulizers, humidifiers, positive airway pressure devices, ventilators, capnographs, and gas analyzers. According to study,
Global Respiratory Monitoring Devices Market | Global Respiratory Monitoring Dev …
Respiration is a unique process of human lives, which jumps at the time of birth and lasts till decease. A healthy human body is skilled of respiration process for numerous years but, due to rising levels of pollution in urban cities and lives concerning tobacco smoking, clogging of airways and other structures of the lung is turning into a common concern across the globe. The respiratory monitoring devices market comprises
Middle East and Africa Respiratory InhalerMarket- AstraZeneca is advancing clini …
Recent Developments AstraZeneca is multinational pharmaceutical and Biopharmaceutical Company. The company provides innovative medicines which are used by millions of people worldwide. AstraZeneca reduces the risk of death and disease progression. The company primarily focuses on development and discovery of cardiovascular, respiratory and inflammation, oncology and infectious disease. To know more:https://www.marketdataforecast.com/market-reports/middle-east-and-africa-respiratory-inhaler-market-6377/ Market Segmentations: Market Data Forecast published a report named Middle East and Africa Respiratory InhalerMarket. It is estimated to grow at a robust
Respiratory Devices Analysis Report of Respiratory Devices in Global Market 2018 …
- Global Respiratory Devices Market: Overview Respiratory devices are medical equipment that assist patients with respiration in a critical care situation. Additionally, respiratory devices are used to deliver medicines to treat several respiratory diseases. Moreover, these devices are used to diagnose respiratory problems in patients. Increase in incidence of COPD and sleep apnea, strategic alliance between key players, and rise in government expenditure are the major factors projected to propel the
Neonatal Respiratory Distress Syndrome Market is driven by high prevalence of re …
Neonatal respiratory distress syndrome, also referred to as infant respiratory distress syndrome is characterized by a particular condition often observed in premature babies, usually born about six weeks before their due dates. During this condition, lungs of the premature infants lose the ability to produce enough surfactants in order to provide oxygen to the body. Surfactants are liquids made up of fat and proteins and it helps the lungs to
Global Respiratory Monitoring Devices Market to Benefit from Increasing Prevalen …
Respiratory disease is a serious public health concern due to rapidly growing number of smokers worldwide. Governments are implementing various health schemes to reduce the death rate caused due to respiratory disease and disorders. Respiratory disease is a medical condition that affects the structure and organs (respiratory system) associated with respiration or breathing. Rise in respiratory diseases such as chronic obstructive pulmonary diseases, asthma, and lung cancer has triggered the growth